Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.85M$5.85Mderived+658.3% vs Q4 2018 Net Income-$10.10M-$10.10MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$12,691,946N/M Operating Cash Flowderived-$5,942,457N/M Free Cash Flowderived-$5,942,458N/M Margins · derivedOperating margin-216.8%+1391.4 pt vs Q4 2018
Net margin-172.5%+1408.0 pt vs Q4 2018
ended Sep 30, 2019 · filed Dec 19, 2019 · 80 d after period end